Showing results (191-200 of 279) with videos related to
Sort By:
Pageof 28
European Journal of Cancer (Oxford, England : 1990)|May 16, 2017
Phase II trial of the PI3 kinase inhibitor buparlisib (BKM-120) with or without enzalutamide in men with metastatic castration resistant prostate cancerAndrew J Armstrong, Susan Halabi, Patrick Healy, et al.Investigational New Drugs|November 29, 2014
A phase II study of sulforaphane-rich broccoli sprout extracts in men with recurrent prostate cancerJoshi J Alumkal, Rachel Slottke, Jacob Schwartzman, et al.Integrative Cancer Therapies|April 7, 2022
Quality of Life of Prostate Cancer Survivors Participating in a Remotely Delivered Web-Based Behavioral Intervention Pilot Randomized TrialCrystal S Langlais, Yea-Hung Chen, Erin L Van Blarigan, et al.Clinical Genitourinary Cancer|December 3, 2014
A phase I study of everolimus and docetaxel in patients with castration-resistant prostate cancerKevin D Courtney, Judith B Manola, Aymen A Elfiky, et al.JAMA Oncology|March 10, 2018
Radiographic Progression-Free Survival as a Clinically Meaningful End Point in Metastatic Castration-Resistant Prostate Cancer: The PREVAIL Randomized Clinical TrialDana E Rathkopf, Tomasz M Beer, Yohann Loriot, et al.European Journal of Cancer (Oxford, England : 1990)|June 1, 2022
Statin and metformin use and outcomes in patients with castration-resistant prostate cancer treated with enzalutamide: A meta-analysis of AFFIRM, PREVAIL and PROSPERAnthony M Joshua, Andrew Armstrong, Megan Crumbaker, et al.Journal of Oncology Practice|August 15, 2013
Prevalence of pain and analgesic use in men with metastatic prostate cancer using a patient-reported outcome measureKaren A Autio, Antonia V Bennett, Xiaoyu Jia, et al.Prostate Cancer and Prostatic Diseases|November 21, 2019
Germline polymorphisms associated with impaired survival outcomes and somatic tumor alterations in advanced prostate cancerWilliam S Chen, Eric L Feng, Rahul Aggarwal, et al.The Lancet. Oncology|April 19, 2015
Effect of enzalutamide on health-related quality of life, pain, and skeletal-related events in asymptomatic and minimally symptomatic, chemotherapy-naive patients with metastatic castration-resistant prostate cancer (PREVAIL): results from a randomised, phase 3 trialYohann Loriot, Kurt Miller, Cora N Sternberg, et al.Clinical Genitourinary Cancer|March 28, 2017
Effect of Visceral Disease Site on Outcomes in Patients With Metastatic Castration-resistant Prostate Cancer Treated With Enzalutamide in the PREVAIL TrialJoshi J Alumkal, Simon Chowdhury, Yohann Loriot, et al.Pageof 28